Commission Approves Use of PrEP in European Union Member States

Last week, the European Commission approved the use of Truvada as Pre-Exposure Prophylaxis (PrEP) in all 28 European Union (EU) member states. This decision paves the way for a reduction in HIV transmission rates throughout Europe, as pharmaceuticals in the member states are regulated by the European Commission, as well as by national governments.

PrEP is a once-daily pill regimen that can help you stay HIV-negative. HRC endorsed the use of PrEP in October 2014, recognizing that when taken as prescribed by a knowledgeable healthcare provider, PrEP has been shown to be safe and highly effective at reducing one’s chances of contracting HIV. PrEP does not protect against other sexually transmitted infections (STIs), but it can be paired with condoms and other safer sex strategies to prevent STIs and unwanted pregnancy.

HRC has consistently pushed the federal government to be more aggressive in its response to the HIV & AIDS epidemic at home and abroad while also educating LGBTQ people and our allies about the current realities of HIV and HIV-related stigma. HIV disproportionately affects members of the LGBTQ community, and despite nearly 30 years of research, there are still 50,000 new cases of HIV each year. Nearly two-thirds of those cases are among gay and bisexual men. In addition, transgender women are far more likely to contract HIV than the general population because of poverty, discrimination, and other structural disadvantages outside of their control.

In addition to the EU, PrEP has now been approved by the U.S., Canada, Kenya, South Africa, Australia, and Peru. To learn more about PrEP, click here.